GSK (NYSE:GSK) Releases FY 2024 Earnings Guidance

GSK (NYSE:GSK) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 2.120-2.160 for the period, compared to the consensus EPS estimate of 3.960. The company issued revenue guidance of $41.2 billion-$41.2 billion, compared to the consensus revenue estimate of $39.6 billion.

GSK Trading Up 0.3 %

Shares of GSK traded up $0.15 during mid-day trading on Friday, reaching $43.50. 4,048,068 shares of the company’s stock traded hands, compared to its average volume of 3,498,257. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.62. The stock’s 50-day moving average is $41.87 and its two-hundred day moving average is $39.14. GSK has a 12 month low of $33.33 and a 12 month high of $43.84. The stock has a market cap of $90.15 billion, a P/E ratio of 15.76, a P/E/G ratio of 1.49 and a beta of 0.65.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The company had revenue of $10 billion for the quarter, compared to the consensus estimate of $9.79 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. Research analysts forecast that GSK will post 4.13 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be issued a $0.3762 dividend. This represents a $1.50 annualized dividend and a dividend yield of 3.46%. This is a boost from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. GSK’s dividend payout ratio is currently 57.61%.

Analyst Ratings Changes

GSK has been the subject of a number of recent research reports. Citigroup raised shares of GSK from a neutral rating to a buy rating in a research report on Tuesday, February 13th. Guggenheim raised GSK from a neutral rating to a buy rating in a research report on Monday, March 4th. Finally, Morgan Stanley started coverage on GSK in a report on Tuesday, January 23rd. They issued an equal weight rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, GSK currently has an average rating of Moderate Buy.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.